F
0.344
0.08 (32.27%)
| Previous Close | 0.260 |
| Open | 0.270 |
| Volume | 5,908,431 |
| Avg. Volume (3M) | 1,917,357 |
| Market Cap | 22,876,132 |
| Price / Book | 138.36 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2025 |
| Diluted EPS (TTM) | -0.210 |
| Total Debt/Equity (MRQ) | 302.81% |
| Current Ratio (MRQ) | 1.14 |
| Operating Cash Flow (TTM) | -12.90 M |
| Levered Free Cash Flow (TTM) | -17.74 M |
| Return on Assets (TTM) | -81.15% |
| Return on Equity (TTM) | -559.73% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | FibroBiologics, Inc. | Mixed | Bearish |
AIStockmoo Score
2.5
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 2.50 |
|
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 21.42% |
| % Held by Institutions | 16.75% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Landscape Capital Management, L.L.C. | 30 Sep 2025 | 350,000 |
| Gts Securities Llc | 30 Sep 2025 | 308,661 |
| Cascade Financial Partners, Llc | 30 Sep 2025 | 298,081 |
| Cerity Partners Llc | 30 Sep 2025 | 125,919 |
| Optivise Advisory Services Llc | 30 Sep 2025 | 110,100 |
| Requisite Capital Management, Llc | 30 Sep 2025 | 109,713 |
| &Partners | 30 Sep 2025 | 100,000 |
| American Institute For Advanced Investment Management, Llp | 30 Sep 2025 | 88,206 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 15.00 (D. Boral Capital, 4,261.73%) | Buy |
| Median | 10.00 (2,807.82%) | |
| Low | 5.00 (HC Wainwright & Co., 1,353.91%) | Buy |
| Average | 10.00 (2,807.82%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 0.250 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 06 Jan 2026 | 15.00 (4,261.73%) | Buy | 0.260 |
| 20 Nov 2025 | 15.00 (4,261.73%) | Buy | 0.325 | |
| HC Wainwright & Co. | 02 Jan 2026 | 5.00 (1,353.91%) | Buy | 0.240 |
| 05 Nov 2025 | 5.00 (1,353.91%) | Buy | 0.370 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |